Within proteins and peptides, both L-asparaginyl and L-aspartyl residues spontaneously degrade, generating isomerized and racemized aspartyl residues. The enzyme protein L-isoaspartate (D-aspartate) O-methyltransferase (E.C. 2.1.1.77) initiates the conversion of Lisoaspartyl and D-aspartyl residues to normal L-aspartyl residues. This "repair" reaction helps to maintain proper protein conformation by preventing the accumulation of damaged proteins containing abnormal amino acid residues. Pcmt1-/-mice manifest two key phenotypes: a fatal seizure disorder and retarded growth. In this study, we characterized both phenotypes and demonstrated that they are linked. Continuous electroencephalogram monitoring of Pcmt1-/-mice revealed that abnormal cortical activity for ϳ50% of each 24-h period, even in mice that had no visible evidence of convulsions. The fatal seizure disorder in Pcmt1-/-mice can be mitigated but not eliminated by antiepileptic drugs. Interestingly, antiepileptic therapy normalized the growth of Pcmt1-/-mice, suggesting that the growth retardation is due to seizures rather than a global disturbance in growth at the cellular level. Consistent with this concept, the growth rate of Pcmt1-/-fibroblasts was indistinguishable from that of wild-type fibroblasts.
Under physiological conditions, L-asparaginyl and L-aspartyl residues in polypeptides spontaneously degrade to L-and Disoaspartyl and D-aspartyl residues with half-times ranging from a few hours to hundreds of days (1) (2) (3) (4) (5) . These abnormal residues can affect both the structure and function of polypeptides and may underlie a portion of the aging-related loss of cellular and tissue function (6 -9) . However, many organisms have evolved a strategy for reversing at least some of this damage by an enzymatic methylation reaction that is targeted directly to peptides and proteins containing the major L-isoaspartyl degradation product. The widely distributed cytosolic protein L-isoaspartate (D-aspartate) O-methyltransferase, also termed protein carboxyl methyltransferase 1 (Pcmt1), 1 can initiate the conversion of L-isoaspartyl residues to L-aspartyl residues by forming the methyl ester of the L-isoaspartyl residue (10) . This ester is then converted, in a nonenzymatic reaction, to an L-succinimidyl residue. Spontaneous hydrolysis of the L-succinimidyl residue produces either an L-aspartyl or an Lisoaspartyl residue. If an L-isoaspartyl residue is produced, additional rounds of methyl esterification, succinimide formation, and hydrolysis eventually convert it to an L-aspartyl residue. This pathway has been experimentally demonstrated both in peptides (11) (12) (13) and in proteins (14, 15) .
The methyltransferase-mediated protein-repair pathway is found in a wide variety of organisms, including bacteria, plants, nematodes, and vertebrates (16 -18) . In mammals, the enzyme is expressed in all tissues, with the highest levels of expression in the brain (19) . The ubiquitous expression of this methyltransferase has led to the hypothesis that it might help to maintain cytosolic proteins in the proper conformation and prevent the accumulation of proteins with damaged amino acid residues. To test this hypothesis and to gain insights into the importance of this enzyme in higher organisms, we recently generated Pcmt1 knockout mice (Pcmt1-/-mice) (19) . At the biochemical level, methyltransferase substrates (i.e., damaged proteins containing L-isoaspartyl residues) accumulated in all tissues of Pcmt1-/-mice; the highest levels were found in the brain. At the whole-animal level, the Pcmt1-/-mice manifested two unmistakable phenotypes: abnormally slow growth and sudden, premature death, beginning at about 22 days of age. Continuous videotape monitoring showed that the sudden death was caused by generalized seizures and that virtually all of the seizures were fatal. Very recently, the occurrence of fatal seizures in Pcmt1 knockout mice was confirmed by another group of investigators (20) .
The observation of fatal seizures in Pcmt1-/-mice highlighted the importance of Pcmt1 gene expression in the central nervous system but at the same time raised a number of new issues for investigation. One was whether the abnormal electrical activity in the brains of the Pcmt1 knockout mice was episodic, as suggested by the continuous videotape monitoring, or pervasive, with the overt seizures simply representing the tip of the iceberg. A second issue was whether the fatal seizures might be mitigated or eliminated by antiepileptic drug therapy. A third issue was whether the absence of Pcmt1 in the brain might lead to a significant abnormality in the metabolism of an abundant aspartate-containing dipeptide in the central nervous system, N-acetylaspartylglutamate (NAAG) (21) . NAAG, a putative excitatory neurotransmitter that has been implicated in seizures, has recently been shown to exist in the brain in the succinimide form (22) . The latter finding raised the possibility that N-acetylisoaspartylglutamate (␤-NAAG) might also exist * This work was supported by National Institutes of Health Grants HL47660 and AG15451-01 (to S. G. Y.) and GM26020 (to S. C.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
ʈ Supported by a Howard Hughes Postdoctoral Fellowship for Physicians. To whom correspondence should be addressed: Gladstone Institute of Cardiovascular Disease, P. O. Box 419100, San Francisco, CA 94141-9100. Tel.: 415-826-7500; Fax: 415-285-5632; E-mail: ekim @gladstone.ucsf.edu. 1 The abbreviations used are: Pcmt1, protein carboxyl methyltransferase 1; NAAG, N-acetylaspartylglutamate; ␤-NAAG, N-acetylisoas-and be a substrate for Pcmt1. ␤-NAAG is an excitatory dipeptide that cannot be catabolized by the dipeptidase that normally cleaves NAAG (23, 24) . Still another issue was whether the retarded growth of the Pcmt1 knockout mice was due to inefficient growth of Pcmt1-deficient tissues (perhaps because of an accumulation of damaged proteins within cells) or was simply due to the seizure disorder. In the current study, we have addressed each of these issues.
MATERIALS AND METHODS
Pcmt1-deficient Mice-The generation of Pcmt1 knockout mice has been described previously (19) . For this study, homozygous Pcmt1-deficient mice (Pcmt1-/-) were produced by intercrossing heterozygous Pcmt1-deficient mice (Pcmt1ϩ/-). All mice were of a mixed genetic background (approximately 50% C57BL/6J and 50% 129/SvJae) unless otherwise stated. Mice were weaned at 21 days of age, fed a chow diet containing 4.5% fat (Ralston Purina, St. Louis, MO), and housed in a full-barrier facility with a 12-h light/dark cycle. Mice were genotyped by Southern blot analysis of genomic DNA prepared from a tail biopsy (19) .
Continuous Electroencephalographic Recordings-The mice were anesthetized with avertin (20 g/g of body weight). A small midline incision was made in the abdomen, and a radiofrequency transmitter (PhysioTel Implant, model TA10EA-F20, Data Sciences International, St. Paul, MN) was inserted into the peritoneal cavity. The peritoneum was then closed, and the two monopolar leads that extended from the transmitter were tunneled subcutaneously to a short cutaneous incision over the skull (extending from the base of the skull to the transverse suture). Two small apertures, located ϳ0.5 cm to the left and right of the sagittal suture and 0.5 cm caudal to the transverse suture, were made in the cranium with sharp forceps. The tips of the electrodes were placed within the epidural space on the surface of the cerebral cortex, and the leads were secured with Krazy Glue (Happ Controls, Oak Grove, IL). The skin incisions over the skull and abdomen were then closed with 5-0 silk sutures. Brain electrical potentials were recorded, either continuously or intermittently, with an MP100 system and AcqKnowledge III software (Biopac Systems, Inc., Santa Barbara, CA).
Treatment of Mice with Antiepileptic Drug Therapy-Antiepileptic drugs were administered by adding them to the chow or to the water. The dosage was based on the fact that mice consume approximately 0.13 g of chow and 0.20 ml of water per gram of body weight per day (25) . In some experiments, valproic acid (Sigma) was added to the water bottle (final concentrations of either 0.6 or 0.9 mg/ml), so that the average daily intake of valproic acid was predicted to be either 120 or 180 g/g. In other experiments, both valproic acid and clonazepam (Sigma) were added to the chow at 1.35 mg and 1.5 g per gram of chow, respectively. The drugs were dissolved in 1.5 liters of ethanol, mixed with 2 kg of mouse chow for 24 h, and then exhaustively dried in a fume hood. The average daily intake of valproic acid and clonazepam was 180 and 0.2 g/g, respectively.
To assess the effects of these interventions on the survival of Pcmt1-/-mice, 21-day-old mice were given valproic acid alone (120 (n ϭ 20) or 180 g/g (n ϭ 11)), a combination of valproic acid and clonazepam (n ϭ 12), or no treatment (n ϭ 11). The food and water in each cage were changed every 3 days.
Analyzing the Growth of Pcmt1-deficient Cells in Culture-To examine the growth characteristics of Pcmt1-deficient cells, we isolated fibroblasts from Pcmt1ϩ/ϩ, Pcmt1ϩ/-, and Pcmt1-/-embryos. Pcmt1ϩ/-mice were intercrossed, and pregnant females were sacrificed at 12.5 days post coitus. Embryos were dissected from the uterus and placenta, and yolk sacs were retained for genotyping. Embryos were incubated in 5 ml of 0.25% trypsin-EDTA (Life Technologies, Inc.) for 8 h at 4°C and then for 20 min at 37°C. The trypsin solution was removed, and the embryos were mechanically disrupted by repeated pipetting in 5 ml of cell culture medium (Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (v/v), L-glutamine, nonessential amino acids, penicillin-streptomycin (all from Life Technologies), and 2-mercaptoethanol (Sigma; final concentration, 100 M)). After the debris had settled settled, the cell suspension was removed, diluted to 1 ϫ 10 ml with medium, and plated in T75 flasks. Approximately 1 ϫ 10 7 cells were obtained from each embryo. The cells were grown in an incubator with 7% CO 2 at 37°C.
The fibroblasts were passaged according to a 3T6 protocol (26) . Cells were trypsinized every 3 days, counted, and replated at a density of 2 ϫ 10 6 cells per 100-mm Petri dish. For 2-and 3-day growth experiments, 1 ϫ 10 4 cells of each line (passage 2) were plated onto eight wells of duplicate 96-well plates. One of the plates was incubated for 12 h and the other plate for 72 h, after which the cell density for each fibroblast cell line was determined with a CellTiter 96 AQ One Solution cell proliferation assay kit (Promega, Madison, WI). The cell growth rate was calculated as the ratio of the 72-h cell density (average of eight wells) to the 12-h cell density (average of eight wells). The growth rates of the Pcmt1ϩ/-and Pcmt1-/-fibroblasts were normalized to the growth rate observed in Pcmt1ϩ/ϩ fibroblasts.
Next we examined the survival characteristics of Pcmt1-/-fibroblasts. Each fibroblast cell line (passage 4) was plated onto 96-well plates at a density of 1 ϫ 10 4 cells per well (eight wells per cell line). The plates were then grown under standard conditions, except that the cell culture medium contained a low concentration of fetal bovine serum (0.5%). The medium was changed every 4 days, and cell survival at various time points from 12 h to 16 days was assessed with the CellTiter 96 AQ kit. The data were expressed as the cells surviving at each time point, relative to the number of cells at the 12-h time point.
In several experiments, equal numbers of wild-type and Pcmt1-/-fibroblasts (passage 3) were mixed and then passaged according to a 3T6 protocol. DNA was isolated from the mixtures at several passages, both before and after immortalization. The ratio of wild-type to Pcmt1-/-fibroblasts in the mixtures at various time points was determined by performing Southern blots of genomic DNA and then analyzing the blots with a phosphor imager (Fuji BioImaging analyzer, BAS 1000 with MacBAS, Fuji Medical Systems, USA, Inc., Stamford, CT).
Measuring Protein L-Isoaspartate (D-Aspartate) O-Methyltransferase Activity-Fibroblasts from a 100-mm plate were lysed in 2 ml of a hypotonic solution (0.1ϫ phosphate-buffered saline) and then disrupted with a Dounce homogenizer. Methyltransferase activity in the cytosolic fraction was assessed by measuring the ability of the extracts to transfer 14 C]AdoMet remains on the filter paper. The filter paper was then removed, and the radioactivity in the vials was counted. In parallel, the [ 14 C]methanol radioactivity was measured in reactions lacking ovalbumin, and that amount of radioactivity was considered to be the background of the assay and was subtracted from the tubes containing ovalbumin. A unit of methyltransferase activity was defined as 1.0 pmol of methyl groups transferred per minute under these conditions. The amount of protein in the cytosol preparations was determined with a Lowry protein assay (27) .
Quantitation of the Damaged Amino Acid Residues-To measure the amount of damaged amino acid residues within cytosol preparations, we used recombinant human L-isoaspartate (D-aspartate) O-methyltransferase to transfer [ 14 C]methyl groups from [ 14 C]AdoMet to damaged aspartyl and asparaginyl residues within cytosolic extracts. The extent of methylation of the cytosolic proteins reflects the extent of the damaged amino acid residues. In its basic format, this assay is similar to the methylation assay described above, except that the proteins in 10 l of fibroblast cytosol were used as the methyl-accepting substrates instead of ovalbumin. In addition, 44.0 units of recombinant human protein L-isoaspartate (D-aspartate) O-methyltransferase (28) were added to the cytosolic extracts to ensure complete methylation of the high affinity L-isoaspartyl/D-aspartyl residues. The methylation reaction was allowed to proceed for 120 min, after which the [ 14 C]methyl esters were quantitated as described above.
Methylation of Aspartyl-containing Neurotransmitters-N-acetyl-Laspartic acid (NAA), NAAG, ␤-NAAG, N-methyl-D-aspartic acid (NMDA), and ␥-aminobutyric acid were obtained from Sigma. The NAAG preparation from Sigma contained an average of 6.5 mol of isopropanol and 1.7 mol of acetone per mol of NAAG. Because those reagents interfere with the methylation assay, they were removed by dissolving the compound in water and then lyophilizing the solution. The ability of each compound to be methylated by human protein L-isoaspartate (D-aspartate) O-methyltransferase was initially assayed for 1 h with recombinant methyltransferase (44.0 units) and [ 14 C]AdoMet, according to the procedures described above. To determine the K m values of those compounds shown to be substrates in the initial assay, various concentrations of ␤-NAAG (0.025-3.2 mM) and NAA (3.3 mM) were methylated as described above, except that 5.5 units of enzyme were used and the incubation time was 11 min in a 1.0 M sodium HEPES buffer, pH 7.5. The kinetic constants for the methylation of these substrates were determined by fitting the data points to the Michaelis-Menten equation with DeltaGraph 4.0 (DeltaPoint, Belleview, WA).
Analysis of NAAG and ␤-NAAG in Mouse Brain and UrinePcmt1-/-and Pcmt1ϩ/ϩ mice were euthanized by cervical dislocation, and the brains were removed rapidly. Cytosolic extracts were prepared as described previously (19) . Urine was also collected from groups of four Pcmt1-/-and four Pcmt1ϩ/ϩ mice housed in metabolic cages. NAAG and ␤-NAAG were isolated with a high performance liquid chromatography system (two model 510 pumps with a U6K injector and a model 441 absorbance detector set to 214 nm), according to published procedures (29) . Aliquots of brain cytosol (100 l, 0.99 -2.14 mg/ml) and urine (100 l) were injected onto an anion-exchange column (Partisil SAX; particle size, 10 m; 250 ϫ 4.6 mm; Alltech) equilibrated in 60 mM monopotassium phosphate, pH 4.5, and the peptides were eluted isocratically at 1.0 ml/min. The peptides were identified and quantified by comparison with synthetic NAAG and ␤-NAAG (15 nmol each), which eluted from the column after 23 and 28 min, respectively.
RESULTS
Analysis of Seizure Activity in Pcmt1-/-Mice-We previously reported that Pcmt1-/-mice die from generalized seizures and that most of the seizures recorded by continuous videotape monitoring were fatal (19) . An analysis of multiple videotaped seizures revealed a characteristic seizure phenotype. First, there were jerky movements for a mean period of 10 s, followed by a period of grooming and ataxia for 10 s. Next, there was a period of vigorous jumping and running for a mean of 4 s, followed by tonic/clonic movements for a mean of 4 s. After the tonic/clonic activity, the mice were motionless and without spontaneous respirations.
To determine whether abnormal brain electrical activity was present during the episodic seizures or was more pervasive, we performed continuous electroencephalographic monitoring in Pcmt1-/-mice and in littermate controls (Pcmt1ϩ/-mice). Abnormal cortical electrical activity, consisting of high amplitude spikes and waves, was present during ϳ50% of each 24-h period for the Pcmt1-/-mice; controls showed no abnormal activity (Fig. 1) . Remarkably, the abnormal electrical activity was present in the Pcmt1-/-mice at the same time that they appeared overtly healthy and active in their cages. Fatal seizures were characterized by high amplitude spikes and waves, followed by diminished cortical activity in the postictal period (Fig. 2) . During the postictal period, spontaneous respiratory activity was absent, and within a short time, the only detectable electrical potentials were cardiac depolarizations.
Treatment of Pcmt1-/-Mice with Antiepileptic Drug Therapy-To determine whether antiepileptic drug therapy might prevent or mitigate the lethal seizure disorder, groups of Pcmt1-/-mice were treated with valproic acid or a combination of both valproic acid and clonazepam. A low dose of valproic acid (120 g/g/day) extended the survival of Pcmt1-/-mice, but by only 10 -15 days (Fig. 3) . A higher dose of valproic acid (180 g/g/day) was more effective in prolonging life span, but the majority of mice still died by 65-75 days of age. The combination of valproic acid (180 mg/kg/day) and clonazepam (0.2 mg/ kg/day) was the most effective in prolonging survival, but even with that regimen, more than 50% of mice died before 85 days and fewer than 25% survived more than 110 days.
Effects of Antiepileptic Drug Therapy on the Growth and Mating Behavior of Pcmt1-/-Mice-Pcmt1-/-mice grew more slowly than Pcmt1ϩ/ϩ littermate controls. At 7 weeks of age, both male and female Pcmt1-/-mice were 2-3 g smaller than their littermates (Fig. 4A) . Initially, we hypothesized that this growth disturbance was due to a global disturbance in cellular metabolism in many tissues, a consequence of the Pcmt1 deficiency and of the accumulation of damaged proteins containing L-isoaspartyl residues. However, the pervasive EEG abnormalities in Pcmt1-/-mice led us to consider an alternative hypothesis: that the retarded growth was due to abnormal brain electrical activity. If that alternative hypothesis were correct, we reasoned that the size difference between Pcmt1-/-mice and their littermates would be reduced or eliminated by antiepileptic drug therapy. To test this possibility, we placed male and female Pcmt1-/-and Pcmt1ϩ/ϩ mice on valproic acid (180 g/g/day) at 21 days of age and weighed them 4 weeks later (Fig. 4, A and B) . Interestingly, antiepileptic drug treatment had no effect on the body weight of Pcmt1ϩ/ϩ mice at 7 weeks of age, but it significantly increased the body weight of Pcmt1-/-mice and eliminated the differences in body weight between Pcmt1-/-and Pcmt1ϩ/ϩ mice.
We also found that the mating behavior was abnormal in Pcmt1-/-mice. We did not observe mounting of Pcmt1-/-females by wild-type males or mounting of wild-type females by Pcmt1-/-males. This was the case even when the mice were treated with the three regimens of anticonvulsant drugs described above. We then performed a mating experiment involving Pcmt1-/-, Pcmt1ϩ/-, and Pcmt1ϩ/ϩ mice in which all of the mice were fed chow containing the combination of clonazepam and valproic acid described above. Ten 6-week-old Pcmt1ϩ/-or Pcmt1ϩ/ϩ female mice were housed with five 6-week-old Pcmt1-/-males for 4 weeks (two females and one male per cage). No vaginal plugs were observed (inspections were performed daily), and none of the female mice became pregnant. Similarly, when seven 6-week-old Pcmt1-/-females were housed with four Pcmt1ϩ/-or Pcmt1ϩ/ϩ males for 4 weeks (one or two females and one male per cage), only one of the To determine whether Pcmt1 deficiency affects the growth rate of cells in culture, early passage Pcmt1-/-, Pcmt1ϩ/-, and Pcmt1ϩ/ϩ primary embryonic fibroblasts were plated at equal densities, and 72-h growth rates were measured. The growth rates for Pcmt1-/-, Pcmt1ϩ/-, and Pcmt1ϩ/ϩ cells were essentially identical; the growth rates for Pcmt1-/-cells (n ϭ 6) and Pcmt1ϩ/-cells (n ϭ 17) were 104.7 Ϯ 5.0% and 106.5 Ϯ 3.7%, respectively, of the growth rate of wild-type cells (n ϭ 5). In addition, Pcmt1 deficiency had no detectable effect on the survival of early passage cells grown under minimal growth conditions (e.g. 0.5% fetal bovine serum) (Fig. 5) . Thus, Pcmt1 deficiency did not affect either the short-term growth or the survival of fibroblasts. In one of the latter experiments, the accumulation of damaged amino acid residues was measured in cytosolic extracts from fibroblasts grown under minimal growth conditions. In this assay, the recombinant human Pcmt1 methyltransferase and [
14 C]AdoMet were used to methylate damaged amino acids within fibroblast cytosolic extracts. Not surprisingly, the Pcmt1-/-cells had nearly 3-fold higher levels of damaged cytosolic proteins (i.e. an increase in methylaccepting protein substrates) than the Pcmt1ϩ/ϩ cells (data not shown).
We next assessed whether Pcmt1 deficiency might perturb the long-term growth of cultured fibroblasts. Todaro and Green (26) described the long-term growth of mouse primary embryonic fibroblasts when passaged according to 3T3, 3T6, and 3T12 protocols. Over the first 10 passages, the growth rate of these cells steadily declines. The cells then undergo a "crisis," during which the growth rate reaches a nadir. This nadir is analogous to a Hayflick limit (30, 31) for senescent human fibroblast cell lines. Unlike senescent human cells, however, senescent mouse fibroblasts are susceptible to spontaneous immortalization, and their growth rate increases several passages after the crisis stage. We were interested in determining whether Pcmt1 deficiency would lead to a premature crisis, a prolonged crisis, or even preclude spontaneous immortaliza- tion. When the cells were grown according to a 3T6 protocol, there were minor differences in the growth rates of fibroblasts isolated from Pcmt1-/-embryos (n ϭ 5) and Pcmt1ϩ/ϩ embryos (n ϭ 6) (Fig. 6) . However, plotting of the growth rates for all 11 cell lines showed that Pcmt1 deficiency had no detectable adverse effect on cell growth.
We also tested the hypothesis that we might be able to uncover a subtle disturbance in the growth of Pcmt1-/-cells, relative to Pcmt1ϩ/ϩ cells, by mixing the cells together and allowing them to compete for growth in the same cell culture dish. For these experiments, equal numbers of early passage fibroblast cell lines were mixed, plated, and then passaged according to a 3T6 protocol. Southern blot analyses were performed on genomic DNA at a number of different passages, and the intensities of the wild-type and knockout bands were measured with a phosphor imager. The ratio of the wild-type and knockout bands was used to gauge the relative numbers of wild-type and knockout cells in each culture before, during, and after the crisis. After 28 passages, the ratio of wild-type and knockout cells varied. However, the number of wild-type/ knockout mixes containing predominantly wild-type cells equaled those containing predominantly Pcmt1-deficient cells (Fig. 7) . These experiments did not support a competitive disadvantage for Pcmt1-deficient cells, compared with wild-type cells.
Assessing Whether N-Acetylisoaspartylglutamate Is a Substrate for the Pcmt1-Methyltransferase-One way in which the absence of the methyltransferase deficiency might cause seizures in Pcmt1-/-mice is by altering the levels of excitatory or inhibitory neurotransmitters. Although the absence of protein repair could diminish the activity of specific proteins involved in neurotransmitter metabolism, Pcmt1 also might be involved more directly, perhaps through methylation of a neurotransmitter. Of interest in this regard is NAAG, an abundant brain dipeptide that is thought to be a neurotransmitter recognized by NMDA receptors, a class of glutamate receptors implicated in the development of seizures (24, 32) . Recently, the succinimidyl form of NAAG has been identified in rat brain (22) , a finding that strongly suggested that the L-isoaspartyl-containing form of NAAG, ␤-NAAG, might also be present because the succinimide would be expected to form both NAAG and ␤-NAAG by spontaneous hydrolysis. ␤-NAAG has two properties of potential relevance to these studies. First, it is active as an excitatory neurotransmitter (24) . Second, it cannot be cleaved by the dipeptidase that hydrolyzes NAAG (23, 24) .
If ␤-NAAG is normally methylated by the methyltransferase in a pathway leading to its conversion to NAAG, it is conceivable that ␤-NAAG would accumulate in the brains of Pcmt1-/-mice. Such an accumulation would be expected to disrupt the balance of excitatory and inhibitory neurotransmitters. To de- Mice were weaned onto a normal chow diet at 21 days of age, and drug therapy was initiated. Body weights were measured at 7 weeks of age. During drug therapy, there were no significant weight differences between male Pcmt1-/-and male Pcmt1ϩ/ϩ mice (23.643 Ϯ 2.427 g (n ϭ 7) versus 23.6 Ϯ 2.131 g (n ϭ 8); p ϭ 0.9715); similarly, there were no weight differences between female Pcmt1-/-and female Pcmt1ϩ/ϩ mice (19.925 Ϯ 2.738 g (n ϭ 4) versus 19.88 Ϯ 1.474 g (n ϭ 10); p ϭ 0.9683). The addition of valproic acid to the chow did not affect the weight of male Pcmt1ϩ/ϩ mice (p ϭ 0.5844) or female Pcmt1ϩ/ϩ mice (p ϭ 0.1959). However, valproic acid caused an increase in the weight of both male Pcmt1-/-mice (p ϭ 0.0327) and female Pcmt1-/-mice (p ϭ 0.0452). All statistical comparisons were made with a two-tailed t test.
termine whether this is in fact the case, we measured NAAG and ␤-NAAG levels in brain cytosolic extracts by high performance liquid chromatography and anion-exchange chromatography (Fig. 8) . No significant differences in NAAG levels in brain extracts were found in brain extracts of Pcmt1ϩ/ϩ and Pcmt1-/-mice, and little or no ␤-NAAG was detected in either extract. Urine samples from Pcmt1ϩ/ϩ and Pcmt1-/-mice were also examined. Interestingly, only ␤-NAAG was detectable in the urine, and the levels were similar in the Pcmt1ϩ/ϩ and Pcmt1-/-mice.
Although the overall levels of the NAAG in whole brains did not appear to be different in the wild-type and knockout mice, these results do not exclude the possibility that Pcmt1 is involved in NAAG metabolism within a specific cellular compartment. Although the latter issue is difficult to address definitively, we reasoned that it would at least be possible to determine whether ␤-NAAG is a substrate for the methyltransferase reaction in vitro. Using recombinant human Pcmt1 and [ 14 C]AdoMet, we found that ␤-NAAG is methylated by the enzyme with a V max of ϳ2300 pmol/min/mg of protein (about 20% of that for ovalbumin (33) ) and a K m of 1.53 mM. We also tested N-acetylaspartate, a breakdown product of NAAG, and found that it was a very low affinity substrate for the methyltransferase, with a V max of only 17% that of ovalbumin and a K m of 87 mM. No methylation was detected with 5 mM NAAG or with other related carboxylic acids, such as 5 mM ␥-aminobutyric acid (an inhibitory neurotransmitter), 2 mM NMDA (the synthetic glutamate receptor agonist), 64 mM L-aspartic acid, or 64 mM L-asparagine.
The fact that ␤-NAAG was recognized and methylated by Pcmt1 (albeit with a relatively low affinity) raised the possibility that Pcmt1 might modulate ␤-NAAG levels in vivo. To further assess this possibility, we performed computer modeling of the spontaneous and enzymatic reactions involved in ␤-NAAG formation and repair (34) . We assumed that the amount of NAAG that can be extracted from Pcmt1ϩ/ϩ mouse brain (determined in this study as 3.06 nmol/mg of soluble protein) corresponds to a concentration of 89 M. The rate constant for the spontaneous formation of the NAAG succinimide intermediate was assumed to be similar to that measured for the peptide VYPDAA (t1 ⁄2 ϭ 266 days at pH 7.4 and 37°C) (2) . The rates of succinimide hydrolysis and racemization were assumed to be the same as those measured for the peptide VYP-Asu-GA, where Asu denotes the aspartyl succinimide (1). The enzymatic methylation of ␤-NAAG was represented by the Michaelis-Menten equation, using the K m (1.53 mM) measured in this study; and the velocity of the reaction (81.2 nM/min) was calculated from the V max measured here and the amount of Pcmt1 activity in wild-type mouse brain (19) . The rate of spontaneous demethylation of the ␤-NAAG-methyl ester was estimated to be similar to that of VYP-(isoAsp-methyl ester)-AA (t1 ⁄2 ϭ 43 min) (2). The change in each component of the pathway from its initial concentration was calculated from the above rate constants for each minute and iterated to give the cumulative changes over the 50 h of simulated time. After 50 h, the levels of ␤-NAAG in the brains of Pcmt1 knockout mice would be predicted to be only about 3% higher than in the wild-type mice, but this estimate is highly dependent on the assumed values in the simulation.
DISCUSSION
The cytosolic protein L-isoaspartate (D-aspartate) O-methyltransferase, or protein carboxyl methyltransferase, can convert isomerized and racemized aspartyl residues to normal L-aspartyl residues (10 -15, 34) . In vitro, the Pcmt1 "repair" reaction actually improves the functional properties of proteins (14, 15) . Mice lacking Pcmt1 are small but otherwise appear grossly normal. Damaged proteins accumulate in their tissues, most notably in the brain, and the mice die suddenly from generalized seizures, typically by 40 -45 days of age (19) . In the current study, we demonstrate that the abnormal brain electrical activity in these mice is not simply a rare stochastic event, as one might have reasonably suspected from the overt phenotype of the mice, but instead is pervasive, occurring for ϳ50% of each 24-h period. Antiepileptic drug therapy with valproic acid or a combination of valproic acid and clonazepam mitigated, but could not prevent, the fatal seizure disorder.
An obvious phenotype of the Pcmt1 knockout mice is retarded growth (19) . Initially, we hypothesized that the retarded growth in the Pcmt1 knockout mice was due to inefficient growth at the cellular level, caused by the widespread accumulation of damaged intracellular proteins (19, 20) . However, the current findings support the viewpoint that the growth disturbance is likely a consequence of the seizure disorder. First, extensive studies of cellular growth in Pcmt1-deficient fibroblasts uncovered no growth abnormality, despite the fact that wild-type fibroblasts express a high level of the enzyme activity and accumulate damaged proteins in its absence. Second, there was no detectable difference in the weights of Pcmt1ϩ/ϩ and Pcmt1-/-mice when they were treated with valproic acid. In those experiments, valproic acid did not measurably affect the weight of Pcmt1ϩ/ϩ mice, but it increased the weight of the Pcmt1-/-mice. Thus, it is reasonable to conclude that the increased weight of valproic acid-treated Pcmt1-/-mice was due to a suppression of seizure activity rather than to an appetite-stimulating effect of the drug.
Another obvious phenotype of the Pcmt1 knockout mice is that the homozygous animals could not mate or reproduce, even when they were treated with the combination of clonazepam and valproic acid. Although it is conceivable that Pcmt1 deficiency in the gonads or endocrine tissues might contribute to the apparent sterility of these animals, several recent observations suggest that the abnormal mating behavior is simply another manifestation of central nervous system dysfunction. First, we recently rescued the lethal seizure disorder in Pcmt1-/-mice with a Pcmt1 transgene under the control of a neuron-specific promoter, 2 and we have documented that the abnormal mating behavior in the rescued Pcmt1 knockout mice is significantly improved. Second, we have noted that spermatozoa from male Pcmt1-/-mice have normal morphology, motility, and ability to fertilize mouse eggs. 2 At this point, the mechanism for the seizures in Pcmt1-deficient mice remains unclear. As soon as we recognized seizures to be a hallmark of Pcmt1 deficiency, we immediately considered the possibility that an inherited form of human epilepsy might map to the PCMT1 locus. We were initially quite intrigued by the fact that Lafora's epilepsy mapped to human chromosome 6q23-25 (35) within a 17-centimorgan region that overlapped with the location of the human PCMT1 gene (6q22.3-24 region) (36) . Although the tissues of Pcmt1-deficient mice did not reveal the characteristic intracellular Lafora inclusion bodies (found in tissues of humans with this form of epilepsy), it seemed conceivable that the Pcmt1-deficient mice simply died before the characteristic pathology developed. To explore this issue, we examined PCMT1 activity levels and PCMT1 heat stability in erythrocytes from human Lafora patients (kindly provided by Dr. Antonio Delgado-Escueta, University of California, Los Angeles, CA), and sequenced the exons of the PCMT1 gene from Lafora disease patients. Neither of these approaches uncovered abnormalities.
3 Subsequent fine mapping studies revealed that the PCMT1 gene maps at least 1.7 megabases telomeric of the D6S311 marker, 3 which represents the telomeric border of the Lafora disease gene (35) . Together, these studies exclude the PCMT1 gene as a culprit in Lafora's epilepsy.
We have also considered the possibility that Pcmt1 might cause epilepsy by directly affecting neurotransmitter metabolism in the brain. We were particularly interested in the dipeptide NAAG, which is abundant in the brain, because it contains 2 E. Kim, unpublished observations. 3 C. G. DeVry and S. Clarke, unpublished observations.
FIG. 8. Identification and quantification of NAAG in brain cell
cytosol from Pcmt1؉/؉ and Pcmt1-/-mice by anion-exchange high performance liquid chromatography. The UV absorbance of the eluent was monitored at 214 nm. The elution positions of NAAG and ␤-NAAG at 23 and 28 min, respectively, were determined with synthetic standards. The top two curves show representative chromatographs of brain cytosol from two Pcmt1ϩ/ϩ mice; the bottom two curves show chromatographs from two Pcmt1-/-mice. We estimated an average content of NAAG to be 3.0 pmol/mg of protein for brain cytosol extracts from two Pcmt1ϩ/ϩ mice and 2.7 pmol/mg of protein for extracts from two Pcmt1-/-mice. Using similar methods, we determined that the concentration of ␤-NAAG in pooled urine samples was 0.31 mol/mg of creatinine/creatine for the Pcmt1ϩ/ϩ mice and 0.41 mol/mg of creatinine/creatine for the Pcmt1-/-mice.
an aspartyl residue that we suspected could isomerize, leading to the formation of the isoaspartyl-containing dipeptide ␤-NAAG. NAAG activates both an ionotropic glutamate receptor (NMDA-type) (32) and the metabotropic glutamate receptor 3 and can be hydrolyzed by a cell-surface dipeptidase (glutamate carboxypeptidase II) into N-acetylaspartyl and glutamate, a neurotransmitter with broader specificity and stronger excitatory activity than NAAG (32, 37) . In experimental animals, high local concentrations of NAAG in the brain cause seizures (38) . In vitro, ␤-NAAG also behaves as a glutamate receptor agonist (21) . Unlike NAAG, however, ␤-NAAG cannot be hydrolyzed by the dipeptidase and, in fact, competitively inhibits NAAG catabolism (23) . Finally, the studies presented in this paper indicate that Pcmt1 does methylate ␤-NAAG, and this methylation reaction would be expected to lead to the conversion of ␤-NAAG to NAAG. These considerations made it appear plausible that Pcmt1 deficiency might lead to an accumulation of ␤-NAAG, which in turn might have a significant impact on brain neurotransmitter metabolism.
However, despite the intuitive attractiveness of a NAAG/␤-NAAG-Pcmt1 connection, our current studies suggest that we should be extremely cautious about the physiologic importance of such a connection. First, both NAAG levels in the brain and ␤-NAAG levels in the urine were quite similar in wild-type and knockout mice. Second, the V max of the methyltransferase reaction was relatively low when ␤-NAAG was the substrate, and computer modeling predicted that the Pcmt1-mediated repair reaction would have only a small impact on the steady-state.
The fact that Pcmt1-/-mice die from fatal seizures indicates that Pcmt1 plays a critical role in the brain. In the initial description of Pcmt1 knockout mice (19) , we demonstrated that the absence of Pcmt1 leads to high levels of substrates for the methyltransferase (i.e., proteins containing isoaspartyl residues) in brain cytosol extracts. Given the accumulation of abnormal proteins in the brain and the ability of isoaspartyl residues within proteins to impair protein function (14, 15) , it seemed reasonable to hypothesize that the seizures might be caused by a defective brain protein-either diminished function of an enzyme, or perhaps a structurally altered protein with a "gain of function." Our current studies do not exclude that scenario. However, it is important to note: 1) that the central nervous system phenotype caused by Pcmt1 deficiency is severe and lethal; 2) that Pcmt1-deficient fibroblasts grow normally, despite the absence of the methyltransferase; and 3) that Pcmt1 deficiency does not cause detectable pathology outside of the central nervous system (at least in young mice), even though there is a substantial accumulation of damaged cytosolic proteins in many tissues. These findings have led us to believe that it may be time to consider the possibility that this protein methyltransferase plays a role in the brain unrelated to protein repair, such as a role in the biosynthesis of a small molecule, perhaps a neurotransmitter, or in the degradation of a small, bioactive compound. As noted earlier, we have doubts that ␤-NAAG is that mysterious small molecule, even though the isomerized version of this molecule is methylated by Pcmt1. In the future, however, we believe that it will be important to continue the search for small molecule substrates for this methyltransferase in the central nervous system. For these studies, the Pcmt1-deficient mice will be a valuable research tool.
